WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H208114
CAS#: 220749-41-7
Description: QLN49417, also known as CDK1 inhibitor 8a, is a selective CDK1 inhibitor. This compound was first reported by Andreani, Aldo; et al in Anti-Cancer Drug Design (2001), 15(6), 447-452. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to Hodoodo Chemical Nomenclature (see web page: https://www.hodoodo.com/page/naming).
Hodoodo Cat#: H208114
Name: QLN49417
CAS#: 220749-41-7
Chemical Formula: C17H11ClN2O
Exact Mass: 294.06
Molecular Weight: 294.740
Elemental Analysis: C, 69.28; H, 3.76; Cl, 12.03; N, 9.50; O, 5.43
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CDK1 inhibitor 8a; CDK1inhibitor8a; CDK1-inhibitor-8a, Cdk1 Inhibitor; QLN49417; QLN-49417; QLN 49417;
IUPAC/Chemical Name: (Z)-3-((2-chloro-1H-indol-3-yl)methylene)indolin-2-one
InChi Key: QJKBRWSJWQVKLY-LCYFTJDESA-N
InChi Code: InChI=1S/C17H11ClN2O/c18-16-12(10-5-1-3-7-14(10)19-16)9-13-11-6-2-4-8-15(11)20-17(13)21/h1-9,19H,(H,20,21)/b13-9-
SMILES Code: ClC(N1)=C(/C=C2C(C=CC=C3)=C3NC/2=O)C4=C1C=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 294.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Mohammed EZ, Mahmoud WR, George RF, Hassan GS, Omar FA, Georgey HH. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs). Bioorg Chem. 2021 Nov;116:105347. doi: 10.1016/j.bioorg.2021.105347. Epub 2021 Sep 11. PMID: 34555628.
2: McDonald IM, Grant GD, East MP, Gilbert TSK, Wilkerson EM, Goldfarb D, Beri J, Herring LE, Vaziri C, Cook JG, Emanuele MJ, Graves LM. Mass spectrometry- based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells. J Biol Chem. 2020 Feb 21;295(8):2359-2374. doi: 10.1074/jbc.RA119.011083. Epub 2020 Jan 2. PMID: 31896573; PMCID: PMC7039562.
3: Lee JY, Yun JS, Kim WK, Chun HS, Jin H, Cho S, Chang JH. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945. Biomed Res Int. 2019 Aug 18;2019:6125068. doi: 10.1155/2019/6125068. PMID: 31531359; PMCID: PMC6720368.
4: Kotoshiba S, Gopinathan L, Pfeiffenberger E, Rahim A, Vardy LA, Nakayama K, Nakayama KI, Kaldis P. p27 is regulated independently of Skp2 in the absence of Cdk2. Biochim Biophys Acta. 2014 Feb;1843(2):436-45. doi: 10.1016/j.bbamcr.2013.11.005. Epub 2013 Nov 21. PMID: 24269842; PMCID: PMC3915056.
5: Szczerbinska I, Gonzales KAU, Cukuroglu E, Ramli MNB, Lee BPG, Tan CP, Wong CK, Rancati GI, Liang H, Göke J, Ng HH, Chan YS. A Chemically Defined Feeder- free System for the Establishment and Maintenance of the Human Naive Pluripotent State. Stem Cell Reports. 2019 Oct 8;13(4):612-626. doi: 10.1016/j.stemcr.2019.08.005. Epub 2019 Sep 12. PMID: 31522974; PMCID: PMC6829768.
6: Lu PH, Yu CC, Chiang PC, Chen YC, Ho YF, Kung FL, Guh JH. Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer. J Urol. 2011 Dec;186(6):2434-41. doi: 10.1016/j.juro.2011.07.088. Epub 2011 Oct 21. PMID: 22019170.
7: Haider C, Grubinger M, Řezníčková E, Weiss TS, Rotheneder H, Miklos W, Berger W, Jorda R, Zatloukal M, Gucky T, Strnad M, Kryštof V, Mikulits W. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther. 2013 Oct;12(10):1947-57. doi: 10.1158/1535-7163.MCT-13-0263. Epub 2013 Aug 12. PMID: 23939380.
8: Squire CJ, Dickson JM, Ivanovic I, Baker EN. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure. 2005 Apr;13(4):541-50. doi: 10.1016/j.str.2004.12.017. PMID: 15837193.
9: Sondhi SM, Goyal RN, Lahoti AM, Singh N, Shukla R, Raghubir R. Synthesis and biological evaluation of 2-thiopyrimidine derivatives. Bioorg Med Chem. 2005 May 2;13(9):3185-95. doi: 10.1016/j.bmc.2005.02.047. PMID: 15809154.